UBE2C-Mediated CD147-CTLA-4 Axis Promotes T Cell Exhaustion and Immunosuppressive Microenvironment in Bladder Cancer

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Immune checkpoint inhibitors (ICIs) show promise in bladder cancer (BCa) treatment, but intrinsic resistance limits efficacy.
• Understanding resistance mechanisms is crucial for improving BCa patient outcomes.

Purpose of the Study:

• To investigate the role of ubiquitin conjugating enzyme E2C (UBE2C) in BCa progression and immune evasion.
• To explore the potential of targeting the UBE2C pathway to overcome ICI resistance in BCa.

Main Methods:

• Utilized syngeneic C57BL/6 BCa models and BCa-CD8+ T-cell cocultures.
• Assessed the impact of UBE2C silencing and overexpression on tumor cell behavior and immune cell function.
• Analyzed key molecular markers including CD147, CTLA-4, IFN-γ, TNF-α, and TGF-β.

Main Results:

• UBE2C promotes BCa proliferation, invasion, and migration while suppressing DNA damage and T-cell abundance.
• UBE2C silencing reduced CD147 and CTLA-4, restored anti-tumor cytokine secretion, expanded CD8+ T-cells, and attenuated tumor growth.
• Overexpression of UBE2C or CD147/CTLA-4 induced T-cell exhaustion and promoted malignant progression.

Conclusions:

• The UBE2C-CD147-CTLA-4 axis is a key driver of BCa immune evasion and progression.
• Targeting this axis can resensitize BCa to immune attack, offering a novel strategy to enhance ICI efficacy.